Re: First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors.
Sam S
SS
Chang
D000970:Antineoplastic Agents; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D018841:HSP90 Heat-Shock Proteins; D006801:Humans; D054833:Isoindoles; D020714:Maximum Tolerated Dose; D009369:Neoplasms
D000970:Antineoplastic Agents; D001549:Benzamides; D018841:HSP90 Heat-Shock Proteins; D054833:Isoindoles; C552103:(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone